Protagonist Therapeutics (PTGX) Total Liabilities (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Total Liabilities data on file, last reported at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 20.9% year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at $42.0 million (down 20.9% YoY), and the FY2025 full-year result was $53.5 million, down 22.97% from the prior year.
• Total Liabilities declined to $42.0 million in Q1 2026, from $53.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $73.3 million in Q2 2024 to a low of $21.3 million in Q4 2023.
• A 5-year average of $46.9 million and a median of $46.5 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities sank 49.07% in 2023 and surged 226.36% in 2024, its largest moves.
• Tracing PTGX's Total Liabilities over 5 years: stood at $32.3 million in 2022, then slumped by 34.18% to $21.3 million in 2023, then surged by 226.36% to $69.4 million in 2024, then decreased by 22.97% to $53.5 million in 2025, then declined by 21.49% to $42.0 million in 2026.
• Business Quant data shows PTGX's Total Liabilities at $42.0 million in Q1 2026, $53.5 million in Q4 2025, and $56.3 million in Q3 2025.